Breaking News Instant updates and real-time market news.

CTRP

Ctrip

$43.46

0.48 (1.12%)

, HPE

HP Enterprise

$17.49

-0.01 (-0.06%)

19:03
05/22/18
05/22
19:03
05/22/18
19:03

On The Fly: After Hours Movers

UP AFTER EARNINGS: Ctrip (CTRP) up 1.4%... Hewlett Packard Enterprise (HPE) up 0.2%. ALSO HIGHER: Arcos Dorados (ARCO) up 4.0% after $60M stock buyback... MetLife (MET) up 1.1% after $1.5B stock buyback. DOWN AFTER EARNINGS: Red Robin (RRGB) down 14.8%... The Container Store (TCS) down 13.1%... Urban Outfitters (URBN) down 2.5%. ALSO LOWER: Curis (CRIS) down 4.4% after 1-for-5 reverse split... Independent Bank Group (IBTX) down 1.0% after merger with Guaranty Bancorp.

CTRP

Ctrip

$43.46

0.48 (1.12%)

HPE

HP Enterprise

$17.49

-0.01 (-0.06%)

ARCO

Arcos Dorados

$7.55

0.35 (4.86%)

MET

MetLife

$48.48

0.405 (0.84%)

RRGB

Red Robin

$57.80

-2.9 (-4.78%)

TCS

Container Store

$8.23

0.68 (9.01%)

URBN

Urban Outfitters

$41.21

-1.09 (-2.58%)

CRIS

Curis

$0.53

0.0211 (4.13%)

IBTX

Independent Bank

$77.85

-0.7 (-0.89%)

  • 22

    May

  • 22

    May

  • 30

    May

  • 05

    Jun

  • 11

    Jun

  • 12

    Jun

  • 10

    Jul

  • 10

    Sep

  • 24

    Sep

CTRP Ctrip
$43.46

0.48 (1.12%)

05/21/18
THCP
05/21/18
UPGRADE
Target $50
THCP
Buy
Ctrip upgraded to Buy from Hold at TH Data Capital
TH Data Capital analyst Tian Hou upgraded Ctrip to Buy with a $50 price target. The analyst expects a traffic recovery to drive better Q1 results when Ctrip reports tomorrow. The company's business has "already stabilized and is on its way to recovery," Hou tells investors in a pre-earnings research note. He sees Q1 as the likely the bottom for Ctrip, and expects its results to recover in the rest of 2018.
05/18/18
OPCO
05/18/18
NO CHANGE
Target $51
OPCO
Outperform
Oppenheimer says would be long-term buyer of Ctrip.com on weakness
Oppenheimer analyst Jed Kelly maintained an Outperform rating and $51 price target on Ctrip.com ahead of the company's Q1 results, which he expects to be in-line with the Street and provide better visibility into valued-added services cross-selling regulation headwinds. In a research note to investors, Kelly said he believes VAS regulation impacts all travel suppliers, but contends that Ctrip.com is best positioned to eventually emerge with greater market share. Kelly said he would be a long-term buyer on weakness.
03/15/18
DBAB
03/15/18
NO CHANGE
Target $48
DBAB
Buy
Ctrip guidance outweighs small margin beat, says Deutsche Bank
Deutsche Bank analyst Eileen Deng believes Ctrip's weaker than expected Q1 revenue guidance outweighs the small margin beat in Q4. In a post-earnings research note titled "Dark cloud on unbundling still overhangs," the analyst lowered her price target fro the shares to $48 from $50 and keeps a Hold rating on Ctrip. Deng is "positive on the enhancing one-stop shop solution, yet cautious on short-term headwinds."
05/21/18
05/21/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Snap (SNAP) upgraded to Neutral from Sell at MoffettNathanson. 2. ProsHoldings (PROS) upgraded to Outperform from Market Perform at Northland with analyst Tim Klasell citing last week's annual user conference and analyst meetings. 3. Ctrip (CTRP) upgraded to Buy from Hold at TH Data Capital with analyst Tian Hou saying the company's business has "already stabilized and is on its way to recovery." 4. Sempra Energy (SRE) upgraded to Buy from Hold at Argus with analyst Jacob Kilstein citing anticipated earnings accretion from the recent purchase of a majority stake in Oncor, favorable regulations, and the growing base rate at its California utilities. 5. Dillard's (DDS) upgraded to Buy from Underperform at BofA/Merrill with analyst Heather Balsky saying she expects improved consumer sentiment, especially in the energy market, to support positive comps and drive multiple expansion. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
HPE HP Enterprise
$17.49

-0.01 (-0.06%)

03/02/18
03/02/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Home Depot (HD), Lowe's (LOW), Tempur Sealy (TPX), Mohawk (MHK), Lumber Liquidators (LL) and Michaels (MIK) initiated with a Hold at Loop Capital. The firm also started Fortune Brands (FBHS) and Wayfair (W) with a Buy. 2. Aflac (AFL), Lincoln National (LNC), Brighthouse Financial (BHF), MetLife (MET) Unum (UNM), Principal Financial (PFG) and Reinsurance Group (RGA) initiated with a Neutral at UBS. The firm also initiated Voya (VOYA) and FGL Holdings (FG) with a Buy and Torchmark (TMK) and American Equity (AEL) with a Sell. 3. HP Enterprise (HPE) initiated with a Neutral at JPMorgan. 4. Caterpillar (CAT), Deere (DE), United Rentals (URI) and Wabco (WBC) initiated with an Overweight, Oshkosh (OSK), Terex (TEX), Cummins (CMI), CNH Industrial (CNHI) and REV Group (REVG) initiated with an Equal Weight and Paccar (PCAR) and Agco (AGCO) initiated with an Underweight at Morgan Stanley. 5. Conatus (CNAT) initiated with an Outperform at Oppenheimer. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/08/18
BERN
05/08/18
NO CHANGE
BERN
Apple, HP Enterprise buybacks offer potential support for stocks, says Bernstein
Bernstein analyst A.M. Sacconaghi, Jr. notes that Apple (AAPL) and HP Enterprise (HPE) have announced large buyback programs with repatriated cash. The analyst sees two impacts from strong repurchases, namely a significant boost EPS to FY18 and FY19 EPS, and potential support for the stock. Overall, Sacconaghi is incrementally positive on Apple following earnings, and continue to see risk-reward on HP Enterprise as favorable.
05/17/18
OTRG
05/17/18
UPGRADE
OTRG
Positive
HP Enterprise upgraded to Positive from Mixed at OTR Global
OTR Global upgraded HP Enterprises to Positive from Mixed following channel checks that indicate a Q2 improvement in business trends in servers and networking, combined with improving win rates and pipeline forecasts, and opportunities from new products.
05/21/18
LOOP
05/21/18
NO CHANGE
Target $23
LOOP
Buy
HP Enterprise has multiple catalysts for next 2-3 years, says Loop Capital
Loop Capital analyst Ananda Baruah kept his Buy rating and $23 price target on HP Enterprise (HPE), saying the company has multiple catalysts for the next 8-12 quarters while generating "incremental earnings" relative to its FY18 guidance. Baruah adds that the company's Tier 1 Cloud computing business with Microsoft (MSFT) is no longer on the decline, while all of its other segments are either flat or growing. The analyst states that these trends are not "well appreciated" by investors, and that the company could "handily" beat on earnings when it reports results tomorrow.
ARCO Arcos Dorados
$7.55

0.35 (4.86%)

MET MetLife
$48.48

0.405 (0.84%)

04/25/18
FBCO
04/25/18
INITIATION
Target $67
FBCO
Outperform
MetLife initiated with an Outperform at Credit Suisse
Credit Suisse analyst Andrew Kligerman started MetLife with an Outperform rating and $67 price target as he believes its low valuation appears not to reflect the less equity-sensitive nature of its strong remaining businesses and likely a 12% ROE by 2020, supported by organic growth, capital management, and sizable cost savings.
03/26/18
03/26/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Intel (INTC) and Analog Devices (ADI) upgraded to Outperform from Market Perform at Raymond James. 2. D.R. Horton (DHI) upgraded to Overweight from Equal Weight at Barclays with analyst Matthew Bouley saying he sees the company as well positioned to absorb volume demand while maintaining gross margins. 3. RBS (RBS) upgraded to Buy from Hold at Deutsche Bank with the firm saying the recent underperformance of shares has brought an attractive entry point. 4. MetLife (MET) upgraded to Overweight from Neutral at Atlantic Equities. 5. Dollar Tree (DLTR) upgraded to Overweight from Neutral at Piper Jaffray with analyst Peter Keith saying he believes the company is making "sensible investments" with Family Dollar to drive comp growth improvement into 2019. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/26/18
BOFA
03/26/18
INITIATION
Target $50
BOFA
Neutral
MetLife reinstated with a Neutral at BofA/Merrill
BofA/Merrill analyst Jay Cohen reinstated coverage of the U.S. Life insurance sector with a positive view, as he believes that the favorable macro backdrop, shifting product mixes, reasonable market conditions and restructuring should support solid performance for many in the sector. As part of that, he started MetLife with a Neutral rating and $50 price target.
03/26/18
ATLE
03/26/18
UPGRADE
ATLE
Overweight
MetLife upgraded to Overweight from Neutral at Atlantic Equities
RRGB Red Robin
$57.80

-2.9 (-4.78%)

05/09/18
05/09/18
UPGRADE
Target $75

Buy
Red Robin upgraded to Buy on improved EPS visibility at Stifel
As previously reported, Stifel analyst Chris O'Cull upgraded Red Robin to Buy from Hold as he believes its EPS visibility has improved given recent segment trends and the company's recent record of outperformance. He also believes its initiatives should help Red Robin sustain positive same-restaurant sales growth for 2018. O'Cull increased his 2018 and 2019 EPS estimates for Red Robin and raised his price target on the stock to $75 from $65.
05/22/18
SPHN
05/22/18
NO CHANGE
Target $80
SPHN
Overweight
Red Robin Q1 traffic outperformed the industry, says Stephens
Stephens analyst Will Slabaugh kept his Overweight rating and $80 price target on Red Robin after its Q1 earnings. The analyst says that while the company missed earnings expectations amid higher selling expenses and softer revenues, he remains positive on its traffic relative to the industry, outperforming for the 7th consecutive quarter.
05/16/18
MAXM
05/16/18
UPGRADE
Target $71
MAXM
Buy
Red Robin upgraded to Buy at Maxim on expected comps and margin increase
As reported earlier, Maxim analyst Stephen Anderson upgraded Red Robin to Buy from Hold and raised his price target to $71 from $60 ahead of next week's earnings. Anderson estimates Q1 comps at 1.5% - above 0.5% consensus - while also noting that "multiple catalysts" can contribute to EPS growth of over 20% for the next two years, potentially triggering a short-covering rally on the stock that has "one of the highest short positions in the restaurant industry at 44% of the float".
05/16/18
MAXM
05/16/18
UPGRADE
Target $71
MAXM
Buy
Red Robin upgraded to Buy from Hold at Maxim
Maxim analyst Stephen Anderson upgraded Red Robin to Buy from Hold and increased his price target on the shares to $71 from $60.
TCS Container Store
$8.23

0.68 (9.01%)

URBN Urban Outfitters
$41.21

-1.09 (-2.58%)

05/21/18
RHCO
05/21/18
NO CHANGE
Target $114
RHCO
Buy
Lululemon price target raised to $114 from $95 at SunTrust
SunTrust analyst Pamela Quintilliano raised her price target on Lululemon (LULU) to $114 and kept her Buy rating as part of her broader research note on Specialty Retail sector. The analyst notes that the adverse weather factors are being overlooked by investors in this market-outperforming space as macro trends appear to be benefiting the consumer. For Lululemon, Quintilliano notes that its inventory to sales ratio at the end of Q4 was among the lowest in the peer group, and that despite the stock's valuation premium of 31.7-times forward PE vs. 25-times historic average, she expects the momentum in the sales of the company's products to benefit its shares. The analyst also favors Buy-rated Chico's FAS (CHS) on its cost-cutting initiatives and operating efficiencies, as well as Urban Outfitters (URBN) based on its "impressive intra-quarter trends" and well controlled promotions. Quintilliano raises her price target on the latter to $47 from $42.
05/16/18
MKMP
05/16/18
UPGRADE
MKMP
Neutral
Urban Outfitters upgraded to Neutral from Sell at MKM Partners
05/16/18
MKMP
05/16/18
UPGRADE
Target $41
MKMP
Neutral
Urban Outfitters upgraded to Neutral at MKM Partners on expected sales rebound
As reported earlier, MKM Partners analyst Roxanne Meyer upgraded Urban Outfitters to Neutral from Sell and raised her price target to $41 from $20. The analyst cites her expectations of a sales and margin recovery in the second half, with Q4 commentary suggesting improving trends after the company's worse than expected performance in 2017. Meyer adds that contrary to her prior view, the improvements at Anthropologie were driven by better assortment and reduced promotional activity rather than easy comps, further noting that Q2 gross margin recovery will become more apparent on "easier markdown compares". The analyst also attributes her new neutral stance to "uncertainty around the success of increased private label at Anthropologie".
05/16/18
05/16/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Urban Outfitters (URBN) upgraded to Neutral from Sell at MKM Partners with analyst Roxanne Meyer citing her expectations of a sales and margin recovery in the second half, with fourth quarter commentary suggesting improving trends after the company's worse than expected performance in 2017. 2. AMD (AMD) upgraded to Neutral from Negative at Susquehanna with analyst Christopher Rolland saying Ethereum prices have doubled in the last month, driving a "modest" reacceleration in GPU purchases, while price hikes have "destroyed value proposition" of a rival Ethereum ASIC. 3. TripAdvisor (TRIP) upgraded two notches to Outperform from Underperform at Macquarie with analyst Matthew Brooks saying TripAdvisor raised their EBITDA forecast to up from flat, and now believes it could grow above 20% in 2018, with a margin rise for the first time since 2011. 4. KKR (KKR) upgraded to Buy from Neutral at Citi with analyst William Katz saying he believes the company's C-Corp conversion will increase relevance of the sector and raise the absolute upside for KKR. 5. Chipotle (CMG) upgraded to Buy from Hold at Argus with analyst John Staszak saying the current valuation does not adequately "reflect prospects for accelerating same-store sales and earnings growth as the company continues its multiyear recovery." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
CRIS Curis
$0.53

0.0211 (4.13%)

10/02/17
RHCO
10/02/17
NO CHANGE
RHCO
Curis stock likely to rally 25% on data, says SunTrust
SunTrust analyst Peter Lawson believes there is a 70% chance that data on Curis' oral PD-L1 inhibitor CA-170 in solid tumors will include partial remissions. The analyst estimates that the stock will jump 25% if patients taking the drug have partial remissions, while the stock will fall 10% if there are no partial remissions. The analyst keeps a $3.50 price target and a Buy rating on the shares.
05/03/18
05/03/18
NO CHANGE

Curis reports Q1 EPS (7c), consensus (9c)
Reports Q1 revenue $2.5M, consensus $2.32M.
10/23/17
GUGG
10/23/17
INITIATION
Target $7
GUGG
Buy
Curis initiated with a Buy at Guggenheim
Guggenheim analyst Adnan Butt initiated Curis with a Buy and $7 price target.
IBTX Independent Bank
$77.85

-0.7 (-0.89%)

05/15/18
RHCO
05/15/18
NO CHANGE
Target $80
RHCO
Hold
Independent Bank price target raised to $80 from $76 at SunTrust
SunTrust analyst Michael Young raised his price target on Independent Bank to $80 to reflect the expectations of higher net interest margins in FY19 and the later closing of the Integrity Bancshares acquisition, saying the company has expanded rapidly by adding $3B in assets through M&A. The analyst adds that the bank is now close to $10B in assets and reaching that threshold would mark a catalyst, but believes the timing of that breach and the "attractiveness" of the assets that it could acquire are difficult to predict. Young keeps his Hold rating on Independent Bank.
07/26/17
HOVD
07/26/17
UPGRADE
HOVD
Outperform
Independent Bank upgraded to Outperform from Market Perform at Hovde Group
07/26/17
KBWI
07/26/17
UPGRADE
Target $71
KBWI
Outperform
Independent Bank upgraded to Outperform from Market Perform at Keefe Bruyette
Keefe Bruyette analyst Brady Gailey upgraded Independent Bank to Outperform with a $71 price target citing the company's "impressive" Q2 results.
06/26/17
SDLR
06/26/17
UPGRADE
Target $70
SDLR
Buy
Independent Bank upgraded to Buy from Hold at Sandler O'Neill
Sandler O'Neill analyst Brad Milsaps upgraded Independent Bank to Buy saying the recent share pullback brings an attractive entry point. The analyst has a $70 price target for the shares.

TODAY'S FREE FLY STORIES

OHI

Omega Healthcare

$31.86

0.07 (0.22%)

21:21
06/24/18
06/24
21:21
06/24/18
21:21
Downgrade
Omega Healthcare rating change at Wells Fargo »

Omega Healthcare…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDT

Medtronic

$86.80

0.51 (0.59%)

20:05
06/24/18
06/24
20:05
06/24/18
20:05
Hot Stocks
MiniMed 670G system real-world data show improved time in range »

Medtronic announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 25

    Jun

  • 26

    Jun

  • 12

    Jul

GE

General Electric

$13.05

0.29 (2.27%)

, AMZN

Amazon.com

$1,715.07

-15.13 (-0.87%)

19:31
06/24/18
06/24
19:31
06/24/18
19:31
Hot Stocks
On The Fly: Top five weekend stock stories »

Catch up on the…

GE

General Electric

$13.05

0.29 (2.27%)

AMZN

Amazon.com

$1,715.07

-15.13 (-0.87%)

BRK.A

Berkshire Hathaway

$286,859.95

2244.95 (0.79%)

BRK.B

Berkshire Hathaway

$188.89

0.05 (0.03%)

JPM

JPMorgan

$105.73

-1.79 (-1.66%)

CMCSA

Comcast

$33.82

1.02 (3.11%)

CMCSK

Comcast

$0.00

(0.00%)

C

Citi

$67.20

-0.43 (-0.64%)

TWTR

Twitter

$45.90

0.68 (1.50%)

MD

Mednax

$44.99

-0.11 (-0.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Jul

  • 26

    Jul

  • 27

    Jul

  • 12

    Oct

  • 14

    Jan

  • 15

    Apr

  • 13

    Jul

  • 15

    Oct

OGE

OGE Energy

$34.95

0.15 (0.43%)

19:25
06/24/18
06/24
19:25
06/24/18
19:25
Downgrade
OGE Energy rating change at Goldman Sachs »

OGE Energy downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWX

Acquired by T

$0.00

(0.00%)

, CMCSA

Comcast

$33.82

1.02 (3.11%)

19:18
06/24/18
06/24
19:18
06/24/18
19:18
Hot Stocks
Box Office Battle: 'Jurassic World: Fallen Kingdom' wins weekend with $150M »

Universal (CMCSA; CMCSK)…

TWX

Acquired by T

$0.00

(0.00%)

CMCSA

Comcast

$33.82

1.02 (3.11%)

CMCSK

Comcast

$0.00

(0.00%)

SNE

Sony

$50.36

1.15 (2.34%)

FOX

21st Century Fox

$48.28

0.31 (0.65%)

FOXA

21st Century Fox

$48.59

0.25 (0.52%)

LGF.A

Lionsgate

$26.90

0.6 (2.28%)

DIS

Disney

$106.37

0.48 (0.45%)

VIAB

Viacom

$30.27

-0.13 (-0.43%)

VIA

Viacom

$35.70

0.15 (0.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Aug

AMZN

Amazon.com

$1,715.07

-15.13 (-0.87%)

, BRK.A

Berkshire Hathaway

$286,859.95

2244.95 (0.79%)

18:53
06/24/18
06/24
18:53
06/24/18
18:53
Periodicals
Amazon/Berkshire/JPMorgan venture takes aim at middlemen, Bloomberg says »

The health venture…

AMZN

Amazon.com

$1,715.07

-15.13 (-0.87%)

BRK.A

Berkshire Hathaway

$286,859.95

2244.95 (0.79%)

BRK.B

Berkshire Hathaway

$188.89

0.05 (0.03%)

JPM

JPMorgan

$105.73

-1.79 (-1.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Jul

  • 12

    Oct

GE

General Electric

$13.05

0.29 (2.27%)

18:42
06/24/18
06/24
18:42
06/24/18
18:42
Periodicals
General Electric nearing deal to sell industrial engines unit, WSJ says »

General Electric is close…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVO

Novo Nordisk

$46.84

0.435 (0.94%)

18:25
06/24/18
06/24
18:25
06/24/18
18:25
Conference/Events
Novo Nordisk to hold an investor and analyst event »

In conjunction with the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

ERYP

Erytech Pharma

$0.00

(0.00%)

18:17
06/24/18
06/24
18:17
06/24/18
18:17
Hot Stocks
Erytech Pharma confirms strategic focus of eryaspase on solid tumors »

Erytech Pharma announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LXRX

Lexicon

$13.58

0.51 (3.90%)

18:12
06/24/18
06/24
18:12
06/24/18
18:12
Hot Stocks
Lexicon announces positive 52-week results from Sotagliflozin inTandem1 study »

Lexicon Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 22

    Mar

PODD

Insulet

$97.37

0.5697 (0.59%)

18:09
06/24/18
06/24
18:09
06/24/18
18:09
Hot Stocks
Insulet presents positive results for Omnipod Horizon Hybrid Closed-Loop System »

Insulet announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LLY

Eli Lilly

$85.90

-0.17 (-0.20%)

18:00
06/24/18
06/24
18:00
06/24/18
18:00
Hot Stocks
Real-World data show advantages in people treated with Eli Lilly's Trulicity »

People with type 2…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

LXRX

Lexicon

$13.58

0.51 (3.90%)

17:56
06/24/18
06/24
17:56
06/24/18
17:56
Hot Stocks
Lexicon announces positive 52-week results from Sotagliflozin inTandem2 study »

Lexicon Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 22

    Mar

DGX

Quest Diagnostics

$112.13

0.93 (0.84%)

17:53
06/24/18
06/24
17:53
06/24/18
17:53
Hot Stocks
Employer wellness programs may reduce risk of developing chronic conditions »

Employer wellness…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LLY

Eli Lilly

$85.90

-0.17 (-0.20%)

17:44
06/24/18
06/24
17:44
06/24/18
17:44
Hot Stocks
New data reinforce potential of Eli Lilly's Ultra Rapid Lispro in diabetes »

Eli Lilly's ultra…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

LLY

Eli Lilly

$85.90

-0.17 (-0.20%)

17:38
06/24/18
06/24
17:38
06/24/18
17:38
Hot Stocks
Eli Lilly announces findings from new analyses of EMPA-REG OUTCOME trial »

Boehringer Ingelheim and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

CTRV

ContraVir Pharmaceuticals

$1.47

-0.06 (-3.92%)

17:30
06/24/18
06/24
17:30
06/24/18
17:30
Conference/Events
ContraVir Pharmaceuticals to hold a business news update conference call »

Management discusses…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZFGN

Zafgen

$6.94

0.32 (4.83%)

17:27
06/24/18
06/24
17:27
06/24/18
17:27
Hot Stocks
Zafgen announces positive full results in phase 2 clinical trial of ZGN-1061 »

Zafgen announced positive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNKD

MannKind

$1.98

0.02 (1.02%)

17:22
06/24/18
06/24
17:22
06/24/18
17:22
Hot Stocks
MannKind presents positive Afrezza clinical data from STAT, AFFINITY studies »

MannKind announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRK

Merck

$61.46

0.295 (0.48%)

16:53
06/24/18
06/24
16:53
06/24/18
16:53
Hot Stocks
Merck presents new data from comparative trials in Type 2 diabetes »

Merck, known as MSD…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 10

    Sep

  • 23

    Oct

NVO

Novo Nordisk

$46.84

0.435 (0.94%)

04:55
06/24/18
06/24
04:55
06/24/18
04:55
Conference/Events
Novo Nordisk to hold an investor and analyst event »

In conjunction with the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

A

Agilent

$62.79

-0.24 (-0.38%)

, ABT

Abbott

$61.93

0.19 (0.31%)

04:55
06/24/18
06/24
04:55
06/24/18
04:55
Conference/Events
American Diabetes Association to hold a conference »

78th Scientific Sessions…

A

Agilent

$62.79

-0.24 (-0.38%)

ABT

Abbott

$61.93

0.19 (0.31%)

AKCA

Akcea Therapeutics

$26.24

0.4 (1.55%)

AMGN

Amgen

$184.86

-1.14 (-0.61%)

AZN

AstraZeneca

$35.06

-0.095 (-0.27%)

BAYRY

Bayer

$0.00

(0.00%)

CL

Colgate-Palmolive

$64.63

1.15 (1.81%)

DXCM

DexCom

$99.52

-0.2 (-0.20%)

LLY

Eli Lilly

$85.90

-0.17 (-0.20%)

IRWD

Ironwood

$19.35

0.74 (3.98%)

JNJ

Johnson & Johnson

$122.81

1.36 (1.12%)

MDT

Medtronic

$86.80

0.51 (0.59%)

MNKD

MannKind

$1.98

0.02 (1.02%)

WAKE

Wake Forest Bancshares Inc.

$0.00

(0.00%)

VLRX

Valeritas

$1.39

0.035 (2.58%)

TNDM

TNDM

SNY

Sanofi

$39.98

0.96 (2.46%)

SIEGY

Siemens

$0.00

(0.00%)

SENS

Senseonics

$4.76

-0.2 (-4.03%)

REGN

Regeneron

$331.82

2.81 (0.85%)

PODD

Insulet

$97.37

0.5697 (0.59%)

NVO

Novo Nordisk

$46.84

0.435 (0.94%)

MRK

Merck

$61.46

0.295 (0.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

  • 25

    Jun

  • 25

    Jun

  • 25

    Jun

  • 25

    Jun

  • 26

    Jun

  • 28

    Jun

  • 02

    Jul

  • 06

    Jul

  • 12

    Jul

  • 17

    Jul

  • 18

    Jul

  • 11

    Aug

  • 27

    Aug

  • 30

    Aug

  • 10

    Sep

  • 06

    Oct

  • 20

    Oct

  • 23

    Oct

  • 28

    Oct

  • 28

    Jan

  • 22

    Mar

AMGN

Amgen

$184.86

-1.14 (-0.61%)

12:23
06/23/18
06/23
12:23
06/23/18
12:23
Hot Stocks
Amgen's Repatha 'significantly reduced' LDL-C, non-HDL-C in Type 2 diabetes »

Amgen announced new data…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LLY

Eli Lilly

$85.90

-0.17 (-0.20%)

12:18
06/23/18
06/23
12:18
06/23/18
12:18
Hot Stocks
Eli Lilly's Trulicity shows promise in delivering efficacy in type 2 diabetes »

Two investigational doses…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

IRWD

Ironwood

$19.35

0.74 (3.98%)

12:14
06/23/18
06/23
12:14
06/23/18
12:14
Hot Stocks
Ironwood announced Praliciguat phase IIa study data »

Ironwood Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.